Hypertrophy and remodeling of the heart in hypertensive patients;Przerost i przebudowa serca u chorych na nadciśnienie tȩtnicze

Nadcisnienie Tetnicze

Volumn 7, Issue 1, 2003, Pages 35-43

  Andrzejak, Ryszard ^a   Porȩba, Rafał ^a   Derkacz, Arkadiusz ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Heart failure; Hypertension; Remodelling

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT INDICATION;

EID: 0037594965     PISSN: 14285851     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Topol E. Cardiovascular Medicine. Lippincott Williams&Wilkins, Philadelphia 2000.
2. Intengan H.D., Schiffrin E.L. Vascular remodeling in hypertension: role of apoptosis, inflammation, and fibrosis. Hypertension 2001; 38: 581-587.
3. Kingwell B.A. Large artery stiffness: implications for exercise capacity and cardiovascular risk. Clin. Exp. Pharmacol. Physiol. 2002; 29: 214-217.
4. Hansson L. Nadciśnienie tȩtnicze i choroby wspólistnieja̧ce. Via Medica, Gdańsk 2001.
5. Krumholz H.M., Larson M., Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am. J. Cardiol. 1993; 72: 310-313.
6. Grohe C., Kahlert S., Lobbert K. i wsp. Modulation of hypertensive heart disease by estrogen. Steroids 1996; 61: 201-204.
7. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalites - the role of insulin resistence and the sympathoadrenal system. N. Engl. J. Med. 1996; 334: 374-381.
8. Sasson Z., Rasoolyr Y., Bhesania T., Rasooly I. Insulin resistence is an important determinant of left ventricular mass in the obese. Circulation 1993; 88: 1431-1436.
9. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 1990; 322: 1561-1566.
10. Post W.S., Larson M.G., Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90: 179-185.
11. McLenachan J.M., Henderson E., Morris K.I., Dargie H.J. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N. Engl. J. Med. 1987; 317: 787-792.
12. Ghali J.K., Kadakia S., Cooper R.S., Liao Y.L. impact of left ventricular hypertophy on ventricular arrhytmias in the absence of coronary artery disease. J. Am. Coll. Cardiol. 1991; 17: 1277-1282.
13. Verdecchia P., Schillaci G., Borgioni C. i wsp. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am. J. Cardiol. 1996; 78: 197-202.
14. Lip G.Y., Beevers M., Beevers D.G. Complications and survival of 315 patients with malignant-phase hypertension. J. Hypertens. 1995; 13: 915-924.
15. Kent R.L., Mann D.L., Cooper G. Signals for cardiac muscle hypertrophy in hypertension. J. Cardiovasc. Pharmacol. 1991; 17: 7-13.
16. Diez J. Current work in the cell biology of left ventricular hypertrophy. Curr. Opin. Cardiol. 1994; 9: 512-519.
17. Weber K.T., Brilla C.G., Campbell S.E., Zhou G., Matsubara L., Guarda E. Pathophysiological hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Pressure 1992; 1: 75-85.
18. Schwarztzkopff B., Frenzel H., Dieckerhoff J. i wsp. Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis. Eur. Heart J. 1992; 13: 17-23.
19. Hamet P., Richard L., Dam T.V. i wsp. Apoptosis in target organs of hypertension. Hypertension 1995; 26: 642-648.
20. Bing O.H.L. Hypothesis: Apoptosis may be a mechanism for the transition to heat failure with chronic pressure overload. J. Molec. Cell Cardiol. 1994; 26: 943-948.
21. Teiger E., Dam T.V., Richard L. i wsp. Apoptosis in pressure-overload-induced heart hypertrophy in the rat. J. Clin. Invest. 1996; 97: 2891-2897.
22. Connor J., Sawczuk S., Benson M.C. i wsp. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13: 119-130.
23. Sadowska W. Echokardiografia kliniczna. Biblioteka Instytutu Kardiologii, Warszawa, 1991.
24. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol. Rev. 1999; 79: 215-262.
25. Grajek S. Patofizjologia przebudowy serca. W: Szyszka A. (red.). Przebudowa serca. Via Medica Gdańsk 2002.
26. Grajek S. Przebudowa serca na poziomie narza̧dowym. Definicje i klasyfikacja. Kardiol. Pol. 1999; 79: 1-4.
27. Grajek S. Rozważania nad funkcja̧ tkanki wlłóknistej w miȩśniu sercowym. Kardiol. Pol. 1992; 36: 285-287.
28. Kajstura J., Zhang X., Reiss K. i wsp. Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing - inducted cardiomyopamyopaphy in rats. Circ. Res. 1994; 74: 383-384.
29. Grajek S. Przebudowa serca na poziomie narza̧dowym. Definicje i klasyfikacja. Kardiol. Pol. 2000; 53: 28-32.
30. Pyda M., Grajek S., Lesiak M. Przerost miȩśnia sercowego. Odmienności przebudowy lewej i prawej tȩtnicy wieńcowej. Kardiol. Pol. 1996; 44: 36-38.
31. Sudhir K., Chou T.M., Hutchinson S.J., Chatterjee K. Coronary vasodilatation induced by angiotensin-converting enzyme inhibition in vivo. Differential contribution of nitric oxide and bradykinin in conductance and resistance arteries. Circulation, 1996; 92: 1734-1739.
32. Szyszka A. Diagnostyka echokardiograficzna przebudowy nadciśnieniowej serca. W: Szyszka A. (red.). Przebudowa serca. Via Medica, Gdańsk 2002.
33. Ganau A., Devereux R.B., Roman M.J. i wsp. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J. Am. Coll. Cardiol., 1992; 19: 1550-1558.
34. Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 1975; 56: 56-64.
35. Savage D.D., Garrison R.I., Kannel W.B. i wsp. The spectrum of left ventricular hypertrophy in general population sample: The Framingham study. Circulation 1987; 75 (supl. I): I26.
36. Kuch-Wocial A., Gaciong Z. Nadciśnienie Tétnicze. W: Hoffman P., Pruszczyk P. (red.). Echokardiografia praktyczna. Warszawa 2001.
37. Serneri G.G., Modesti P.A., Boddi M. i wsp. Cardiac growth factors in human hypertrophy. Relations with myocardial contractility and wall stress. Circ. Res. 1999; 85: 57-67.
38. Danser A.H., van Kesteren C.A., Bax W.A. i wsp. Prorenin, renin, angiotensinogen and angiotensin-converting enzyme in normal and failing human hearts: evidence for renin binding. Circulation 1997; 96: 220-226.
39. Sadoshima J., Izumo S. Molecular characterization of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac: critical role of the AT1 receptor subtype. Circ. Res. 1993; 73: 413-423.
40. Johnston C.I. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repail and remodeling. Hypertension 1994; 23: 258-268.
41. Harrap S.B., Dominiczak A.F., Fraser R. i wsp. Plasma angiotensin II predisposition to hypertension and left ventricular size in young adults. Circulation 1996; 93: 1148-1154.
42. Lee S.C., Stevens T.L., Sandberg S.M. i wsp. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J. Card. Fail. 2002; 8: 149-154.
43. Takahashi T., Allen P.D., Lacro R.V. i wsp. Expression of dihydropyridine receptor (Ca2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J. Clin. Invest. 1992; 90: 927-935.
44. Tsutamoto T., Wada A., Maeda K. i wsp. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-516.
45. Baig M.K., Mahon N., McKenna W.J. The patophysiology of advanced heart failure. Am. Heart J. 1998; 135 (supl.): 216.
46. Hansson M. Natriuretic peptides in relation to the cardiac innervation and conduction system. Microsc. Res. Tech., 2002; 58: 378-386.
47. Mills R.M., Hobbs R.E., Young J.B. BNP for heart failure: role of nesiritide in cardiovascular therapeutics. Congest. Heart Fail. 2002; 8: 270-273.
48. Bryant D., Becker L., Richardson J. i wsp. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor. Circulation 1998; 97: 1375-1381.
49. Sun Y., Weber K.T. Angiotensin II and aldosterone binding: response to chronic angiotensin II or aldosterone administration. J. Lab. Clin. Med. 1993; 122: 404-411.
50. Weber K.T., Sun Y., Guarda E. Structural remodelling in hypertensive heart disease and the roles of hormones. Hypertension 1994; 23: 869-877.
51. Rossi G.P., Sacchetto A., Visentin P. i wsp. Changes in left ventricular anatomy and function in hypertension and pimary aldosteronizm. Hypertension 1996; 27: 1039-1045.
52. Meggs L.G., Ben-Ari J., Gammon D., Goodman A.J. Myocardial hypertrophy: the effect of sodium and role of sympathetic nervous system activity. Am. J. Hypertens. 1988; 1: 11-15.
53. Lind L., Berne C., Lithell H. Prevalence of insulin resistance in essential hypertension. J. Hypertens. 1995; 13: 1457-1462.
54. Zile M.R., Brutsaert D.L. Nowe koncepcje dysfunkcji rozkurczowj i rozkurczowj niewydolnosẃci serca - czȩść I. Rozpoznanie, rokowanie i pomiary czynności rozkurczowej. Circulation 2002; 105: 1387-1393.
55. Brutsaert D.L., Sys S.U. Diastolic dysfunction in heart failure. J. Heart Failure 1997; 3: 225-241.
56. Cuocolo A., Sax F., L., Brush J.E. i wsp. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension. Diastolic mechanism for systolic dysfunction during exercise. Circulation 1990; 81: 978-986.
57. Witkowska M. Co dziś trzeba wiedzieć o rozkurczowej niewydolności serca. Kardiol. Pol. 2001; 55: 603-606.
58. Yamada H., Goh P.P., Sun J.P. i wsp. Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: Clinical application of the Canadian consensus guideline. J. Am. Echocardiogr. 2002; 15: 1238-1244.
59. Thomas J.D., Weyman A.E. Echocardiographic Doppler evaluation of ventricular diastolic function: physics and physiology. Circulation 1991; 77: 977-990.
60. Kasprzak J.D., Drożdz□ J., Krzemińska-Pakuła M. Nieinwazyjna ocena zaburzeń funkcji rozkurczowej. Co nowego? Kardiologia Współczesna 1999; 194-199.
61. Langenfeld M.R.W., Schmieder R.E. Salt and left ventricular hypertrophy: what are the links? J. Hum. Hypertens. 1995; 9: 909-916.
62. MacMahon S.W., Wilcken E.L., MacDonald G.J. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young overweight hypertensive patients. J. N. Engl. Med. 1986; 314: 334-339.
63. Grodzicki T., Baron T. Farmakoterapia przebudowy serca. W: Szyszka A. (red.). Przebudowa serca. Via Medica, Gdańsk 2002.
64. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. 1992; 5: 95-110.
65. Isobe N., Taniguchi K., Oshima S. i wsp. Candesartan cilexetil improves left ventricular function, left ventricular hypertrophy, and endothelial function in patients with hypertensive heart disease. Circ. J. 2002; 66: 993-999.
66. Cuspidi C., Muiesan M.L., Valagussa L. i wsp. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens. 2002; 20: 2293-2300.
67. Su S.F., Hsiao C.L., Chu C.W., Lee B.C., Lee T.M. Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. Am. J. Cardiol. 2000; 86: 514-518.
68. Takemoto M., Node K., Nakagami H. i wsp. Statins as. antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 2001; 108: 1429-1437.
69. Kreuzer J., Watson L., Herdegen T., Loebe M., Wende P., Kubler K. Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II-mediated signal transduction: suppression of c-jun and c-Fos in human smooth muscle cells in vitro. Eur. J. Med. Res. 1999; 4: 135-143.
70. Kannel W.B. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-1576.